Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06401356 · ClinicalTrials.gov registry record · Phase 3
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
A Phase 3 study of Solid Tumor and Hematologic Malignancy, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 15
- Study locations
NCT06401356 is a Phase 3 study of Solid Tumor and Hematologic Malignancy that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 50 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower). The trial reports 15 study locations across 6 states.
The verdict
NCT06401356, a Phase 3 study of Solid Tumor and Hematologic Malignancy, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).
Conditions Studied
Interventions
- DRUG Pelabresib
Study Locations (15)
Other
- ZNA Cadix-Hematology - Antwerp
- Az St-Jan Brugge-Oostende A.V. - Bruges
- AOU Careggi (Department of Experimental and Clinical Medicine) - Florence
- Azienda Ospedaliero - Universitaria Maggiore della Carità (SCDU Ematologia) - Novara
- AO Ospedale di Circolo, PO Varese (Ematologia) - Varese
- Amsterdam UMC location Vumc (Hematology) - Amsterdam
- Cardiff and Vale University Health Board - University Hospital Wales (Hematology) - Cardiff
- Beatson West of Scotland Cancer Centre (Hematology) - Glasgow
- Guys and St Thomas' Hospital - Haematology - London
New York
- Mount Sinai Hospital - Oncology - New York
- Weill Cornell Medicine - New York Presbyterian Hospital (Oncology) - New York
California
- Hematologic Malignancy/Stem (Department of Medicine, Division of Hematology/Oncology) - Los Angeles
Florida
- Mayo Clinic (Cancer Clinical Research Office) - Jacksonville
Illinois
- Northwestern Memorial Hospital (Oncology) - Chicago
Michigan
- UMHS - University of Michigan Medical Center (Radiation Oncology) - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06401356
The ClinicalTrials.gov registry entry for NCT06401356 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Pelabresib is the first listed.
NCT06401356 reports 15 study locations spanning 6 distinct geographic areas - top geographies include Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT06401356 about?
NCT06401356 is a clinical study titled "An Extension Study for Patients Previously Enrolled in Studies With Pelabresib". The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants ...
What is the current status of trial NCT06401356?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2024-08-13. Estimated completion is 2027-06-30.
What conditions does trial NCT06401356 study?
This clinical trial studies the following conditions: Solid Tumor, Hematologic Malignancy, Advanced Malignancies.
What interventions are being tested in trial NCT06401356?
The interventions under investigation include: Pelabresib (DRUG).
Who is sponsoring clinical trial NCT06401356?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06401356 being conducted?
This trial has 15 study locations across California, Florida, Illinois, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.